Should this reaction enter a design campaign?
Biomatter sells custom enzymes, designed from the reaction and tested in the lab. This desk is the question that comes first: does the public evidence, as compiled on 16 October 2026, support spending that campaign — or is the question the wrong one? It does not design a sequence, and it does not report a catalytic activity the ledger does not contain.
- A matching paper is a narrow precedent, not your kcat.
- A fold or a binder score is the wrong problem.
- Silence in the ledger is a refusal, not a negative experiment and not a success.
Write the reaction
Programme licence
USD 100,000 a year, one process-chemistry group.
The signer is a Head of Biocatalysis, a Head of Process Chemistry, or a VP of R&D who is about to fund an enzyme campaign. The licence is the private desk, the frozen ledger with its limits printed on every memo, and four campaign reviews. A second group is a second licence. This page does not take a card.